Moderna’s (MRNA) cancer-vaccine rally hit a setback on Thursday as shares slid toward their worst week in three months and Mizuho analyst Jared Holz warned that extreme volatility made the stock a “do-not-trade” for many investors.

Investors were awaiting full data from the late-stage trial of intismeran autogene plus Merck’s Keytruda at the European Society for Medical Oncology Congress on4.

When the coronavirus SARS-CoV-2 turned our world upside down, mRNA vaccines against COVID-19 brought a breakthrough. Their success established modified mRNA as a powerful foundation for vaccines and opened the way for new mRNA-based technologies,

According to The Fly, Citi said some investors were “assigning value to an effective-cure narrative and success across additional solid tumors.” ・Citi maintained its ‘Sell’ rating on Moderna with an $80 price target.

A needle-free vaccination method protected mice against the viruses that cause COVID-19 and flu, offering a possible new way to deliver mRNA vaccines while limiting unwanted inflammation.

ETFs bought $114.9 million of Moderna (MRNA) shares on Wednesday, Oct. 21, with 20 funds buying and 10 selling.

In vivo CAR-T therapy requires durable, yet transient CAR expression coupled with efficient, T cell-specific delivery. This webinar will

A ‘sell-the-news reaction’? The experimental treatment helped prevent the return of cancer or death in melanoma patients by 42% after two years.